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This population-based study examines prognostic factors and survival trends among adults (15–99 years) diagnosed with small
intestinal cancer in England and Wales during 1971–1990 and followed up to 1995. During this period, the 1- and 5-year age-
standardised relative survival rates for small intestinal cancers combined were 42% and 23%, respectively. Duodenal tumours,
adenocarcinomas, men, patients with advanced age and the most deprived patients had the poorest prognosis. For all small bowel
tumours combined, the excess risk of death fell significantly by 6–9% every 4 years over the 20-year period (adjusted excess hazard
ratio (EHR) 0.91 at 1 year after diagnosis, 0.94 at 5 years). For duodenal tumours, the EHR fell by about 14% (95% CI 5–22%) every
4 years between 1979 and 1990, and a similar trend for jejunal tumours was of borderline significance. Further population-based
investigations linking survival data to individual data on diagnostic methods and types of treatment are needed.
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The small intestine constitutes 75% of the length of the alimentary
tract, but accounts for only 1–2% of gastrointestinal cancers
(Wiggers, 2002). The duodenum, jejunum and ileum vary in
function and in the biochemical composition of food end products
that flow through them (Chow et al, 1996). Small intestinal cancers
are heterogeneous: the predominant morphologic type varies with
the anatomic site, and cancers of the same type behave differently
at different sites.
Few population-based studies of small intestinal malignancy
exist, and what is known of its survival derives mostly from small
hospital case series. No consensus exists on whether survival varies
with the anatomic origin of the tumour (Zar et al, 1996; Howe et al,
1999; Howe et al, 2001). In England and Wales, survival from
small intestinal cancer in adults improved between 1971 and 1995
(Coleman et al, 1999). These trends may be due to change in the
relative frequency of cancers with better or worse prognosis, or
availability of and accessibility to more effective diagnostic
methods and treatment, and/or diagnosis at an earlier and more
treatable stage.
This population-based study was designed to describe the
epidemiology of small intestinal cancer, to examine survival trends
and to explore the impact of prognostic factors on trends in excess
mortality from tumours arising in different parts of the small
bowel.
MATERIALS AND METHODS
Data
A detailed description has been published (Coleman et al, 1999).
Briefly, as part of the national cancer registration scheme (OPCS,
1990), the Office for National Statistics (ONS) compiled data on
individual cancer patients in the National Cancer Registry (NCR)
from 12 regional cancer registries in England and Wales. Linkage
to the National Health Service Central Register (NHSCR), a
virtually complete national person index, provides the NCR with
notification of the eventual death or emigration of any patient with
cancer whose record is flagged at NHSCR.
We extracted data for all patients diagnosed aged 15–99 years
with a primary malignancy of the small bowel in England and
Wales between 1 January 1971 and 31 December 1990 and followed
up to the end of 1995. After the exclusion of 925 patients, mainly
because of multiple/synchronous tumours (30 patients), unknown
survival (591), age below 15 or above 99 (eight) or unknown vital
status (296), 5612 subjects (86% of those eligible) were included in
the analyses. Patients with lymphoma of the small intestine were
not included in this study.
Information available for each patient included sex, date of
birth, date of diagnosis, morphological and anatomic site codes,
vital status and date of death, NHS Region and deprivation
category. The Carstairs index was used as a measure of deprivation
(OPCS, 1990), estimated at the level of the census enumeration
district (ED, mean population 500). A deprivation category was
assigned on the basis of the patient’s ED of residence at diagnosis,
using contemporary dictionaries of correspondence between
postcode of residence and ED.
Received 3 August 2006; revised 8 September 2006; accepted 11
September 2006; published online 10 October 2006
*Correspondence: Dr N Pashayan; E-mail: np275@medschl.cam.ac.uk
British Journal of Cancer (2006) 95, 1296–1300
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yTumours located in the jejunum only became separately
identifiable from other small bowel tumours from 1979, with the
introduction of the ninth edition of the International Classification
of Diseases (ICD-9) (World Health Organization, 1977), so the data
were examined in five 4-year periods of diagnosis (1971–1974,
1975–1978, 1979–1982, 1983–1986 and 1987–1990). Patients were
censored alive from analysis on the date of emigration or 31
December 1995, whichever was earlier.
Trends in the distribution of cases by tumour and patient factors
were examined with a score test for linear trend. Relative survival
up to 5 years was estimated for England and Wales by age, sex,
anatomic localisation, morphologic type and calendar period of
diagnosis, using a maximum likelihood method for individual
tumour records (Este `ve et al, 1990). Relative survival reflects the
excess mortality in the cancer patient group relative to the
expected or background mortality in the general population. It can
be considered as survival in the absence of other causes of death
(competing mortality), which itself varies widely between popula-
tion subgroups. The life tables used to represent the expected
mortality incorporated death rates for England and Wales by
single year of age at death (15–99), sex and every combination of
deprivation category, NHS Region and calendar period (1971–
1985, 1986–1995) (Coleman et al, 1999). National estimates of
relative survival do incorporate regional differences in background
mortality, but results are not presented here by NHS Region.
Relative survival estimates at 1 and 5 years after diagnosis were
age-standardised, with weights given by the distribution across five
age groups (15–49, 50–59, 60–69, 70–79 and 80–99 years) of
adults diagnosed with small intestinal cancer during 1987–1990.
The choice of standard weights is arbitrary, but the age-
standardised estimates are not widely different from the raw
estimates, and they enable direct comparison of relative survival
over time, compensated for changes in the age distribution of
patients.
The simultaneous effects of covariates on relative survival were
estimated with regression models as the excess hazard ratio (EHR)
(Dickman et al, 2003). Follow-up time was divided into yearly
intervals, and models were estimated both for the first year and up
to the fifth anniversary of diagnosis. The significance of main
effects, linear trends and interactions between follow-up time and
other covariates was assessed by likelihood ratio tests at the 5%
level. A forward-fitting strategy was used to select variables that
contributed significantly to the final model. Analyses were done in
STATAs 7.0 (Stata Corp, 2001).
RESULTS
Characteristics
Almost two-thirds (58%) of cases arose in people aged 60–79 years
(Table 1). There was little difference between men and women.
During 1987–1990, duodenum was the most common subsite
(29%), followed by ileum (21%) and jejunum (10%), but for more
Table 1 Small intestinal cancer: number of patients and distribution (%) of tumour and patient characteristics by period of diagnosis: England and Wales
adults (15–99 years) diagnosed 1971–1990
Period of diagnosis
All
1971–1974 1975–1978 1979–1982 1983–1986 1987–1990 periods P-trend
a
No. of patients 1012 1091 1107 1200 1202 5612
Tumour characteristics
Subsite
Duodenum 24.3 26.1 25.3 25.6 28.9 26.1 0.034
Jejunum —
b —
b 13.6 12.0 10.1 7.4 0.008
c
Ileum —
b —
b 25.3 24.8 21.4 14.9 0.026
c
Other 44.4 41.3 3.3 1.7 1.5 17.4 0.002
c
Unspecified 31.3 32.5 32.4 35.9 38.1 34.2 o0.001
Morphology
Adenocarcinoma 41.4 41.2 45.8 48.3 50.5 45.7 o0.001
Endocrine tumour 13.0 13.4 15.1 16.6 13.5 14.4 0.247
Sarcoma 12.5 9.3 10.0 10.7 7.5 9.9 0.003
Other 33.1 36.1 29.1 24.4 28.5 30.0 o0.001
Patient characteristics
Sex
Male 53.6 53.6 49.3 50.1 49.3 50.5 0.06
Female 46.4 46.4 50.7 49.9 50.7 49.5 0.06
Age at diagnosis (years)
15–49 11.4 13.2 9.5 10.6 10.9 11.1 0.236
50–59 20.0 20.2 18.3 17.1 16.5 18.3 0.006
60–69 32.2 27.4 31.6 28.1 29.2 29.6 0.237
70–79 25.5 28.9 28.2 32.1 27.9 28.6 0.074
80–99 10.9 10.3 12.4 12.1 15.5 12.4 o0.001
Deprivation
d
Affluent 18.3 17.7 19.9 19.9 21.9 19.7 0.016
2 21.1 24.4 21.3 22.2 20.5 21.9 0.296
3 22.7 21.2 21.8 21.3 21.9 21.7 0.806
4 20.3 20.4 19.5 20.2 19.1 19.9 0.525
Deprived 17.6 16.3 17.5 16.4 16.6 16.8 0.653
aP-value derived from score test for trend.
bNo data – jejunum and ileum were separately identified only from 1979, in ICD-9 (see text).
cApplies for periods 1979–1990.
dTotal
N¼5237, but 375 (7%) cases could not be assigned to a deprivation category (see text).
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1987–1990, half of all small bowel tumours were adenocarcinomas
(51%), but this varied widely with subsite, from jejunum (67%) to
ileum (37%) (Po0.001). Similarly, endocrine tumours comprised
14% of all tumours, varying widely from ileum (33%) to
duodenum and jejunum (2%).
Relative survival
Age-standardised relative survival for all small intestinal tumours
combined was 42% at 1 year, 28% at 5 years and 19% at 10 years.
Among tumours of specified subsite, duodenal tumours had the
lowest survival (29% at 1 year, 13% at 5 years) and ileal tumours
the highest (56%; 34%). Among tumours of specified morphology,
endocrine tumours had the highest survival (66% at 1 year, 46% at
5 years). Relative survival for duodenal adenocarcinomas was 42%
(standard error (s.e.) 1.7%) at 1 year and 15% (s.e. 1.3%) at 5 years,
significantly lower than for adenocarcinomas arising either in the
jejunum (60% (s.e. 2.8%) and 26% (s.e. 2.7%)) or in the ileum
(57% (s.e. 2.7%) and 25% (s.e. 2.5%)).
Over the 20-year period 1971–1990, the mean absolute increase
in age-adjusted relative survival every 4 years was 3.1% at 1 year
after diagnosis (Po0.001) and 1.1% at 5 years (P¼0.009), but only
0.5% at 10 years (P¼0.421; Figure 1).
Prognostic factors
Compared to patients with duodenal tumours (reference category),
those with ileal and jejunal tumours had a 35–40% lower excess
risk of death within the first 5 years (EHRs 0.60–0.65, adjusted for
all other covariates; Table 2). Patients with endocrine tumours only
had about half the excess mortality (EHR 0.48) of those with
adenocarcinoma (reference group). Women had 8–13% lower
excess mortality than men. The excess risk of death in the first year
after diagnosis was 33% higher among the most deprived than the
most affluent patients (adjusted EHR 1.33, 95% CI 1.17–1.52), and
the excess hazard was still 22% higher over the first 5 years after
diagnosis, with a clear gradient across socio-economic groups
(P-trend o0.001).
Trends in the excess risk of death
Overall, there was a significant 6–9% fall every 4 years in the
excess risk of death from small bowel tumours, both at 1 year after
diagnosis (EHR 0.91) and at 5 years (EHR 0.94; Table 2).
Compared with patients diagnosed during 1971–1974, the adjusted
excess risk of death for those diagnosed during 1987–1990 had
fallen to 0.65 at 1 year after diagnosis and to 0.74 at 5 years.
Time trends in the excess hazard of death from tumours in each
part of the small bowel were less clear-cut. For duodenal tumours,
the excess risk of death at 1 year fell significantly by 26% (EHR
0.74) in the 8 years between 1979–1982 and 1987–1990, after
adjustment for age, deprivation and morphology (average fall 14%
every 4 years, EHR 0.86, P-trend¼0.004), and the excess hazard at
5 years also fell by about 10% every 4 years (Table 3). The excess
risk of death for jejunal tumours fell at a similar rate, but the
numbers of patients and deaths were smaller than for duodenal
tumours, and this trend was of borderline significance (P-
trend¼0.090). The excess risk of death at 1 year also fell for ileal
tumours, but the trend was not statistically significant.
DISCUSSION
To our knowledge this is the first population-based study to
examine survival from small intestinal tumours separately by
morphology, subsite and socio-economic deprivation. The large
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Figure 1 Age-standardised relative survival for small intestinal tumours,
adults (15–99 years) diagnosed in England Wales 1971–1990, followed up
to 1995: by period of diagnosis.
Table 2 Adjusted excess hazard ratio (EHR) and 95% confidence
intervals (CI) at 1 year and 5 years after diagnosis, by prognostic factor:
small intestinal malignancy, England and Wales, adults diagnosed 1971–
1990 and followed up to 1995
Adjusted excess hazard ratio (EHR)
a
1 year 5 years
Period of diagnosis EHR 95% CI EHR 95% CI
1971–1974 1.00 — 1.00 —
1975–1978 0.87 0.77–0.99 0.87 0.80–1.00
1979–1982 0.84 0.74–0.96 0.89 0.83–1.03
1983–1986 0.82 0.72–0.93 0.86 0.80–0.99
1987–1990 0.65 0.57–0.74 0.74 0.69–0.86
Trend
b 0.91 0.89–0.94 0.94 0.92–0.96
Subsite
Duodenum 1.00 — 1.00 —
Jejunum 0.59 0.50–0.71 0.65 0.57–0.75
Ileum 0.62 0.53–0.72 0.65 0.57–0.73
Other 1.11 0.81–1.54 1.12 0.86–1.47
Unspecified 0.86 0.76–0.97 0.78 0.70–0.86
Morphology
Adenocarcinoma 1.00 — 1.00 —
Endocrine tumour 0.48 0.41–0.56 0.48 0.42–0.54
Sarcoma 0.72 0.61–0.83 0.91 0.81–1.02
Other 1.92 1.76–2.09 1.61 1.49–1.73
Sex
Male 1.00 — 1.00 —
Female 0.87 0.81–0.94 0.92 0.86–0.98
Age at diagnosis (years)
15–59 1.00 — 1.00 —
60–69 1.22 1.10–1.36 1.19 1.09–1.29
70–79 1.58 1.43–1.76 1.42 1.31–1.55
80–99 2.46 2.16–2.79 2.13 1.91–2.39
Deprivation
Affluent 1.00 — 1.00 —
2 1.01 0.89–1.14 0.97 0.88–1.07
3 1.04 0.92–1.17 0.97 0.88–1.08
4 1.24 1.09–1.40 1.11 1.00–1.23
Deprived 1.33 1.17–1.52 1.22 1.09–1.36
aAdjusted for each covariate in the table by stepwise addition, with likelihood ratio
test of the significance of the variable on the goodness of fit of the model.
bRatio of
the excess hazard of death between successive calendar periods of diagnosis, after
adjustment for other covariates in the Table.
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up to 25 years of follow-up also enabled analysis of survival trends
for these rare tumours.
The anatomic origin of the tumour is a significant prognostic
factor. Ileal tumours had the highest survival, followed by
those of the jejunum and duodenum. Survival has not been
shown to vary with subsite in small case series from single
institutions (Zollinger, 1986; Cunningham et al, 1997; Ojha
et al, 2000). Other studies (Ashley and Wells, 1988; Frost et al,
1994) have shown slightly more favourable prognosis for
duodenal adenocarcinomas. However, hospital-based series are
prone to selection bias. Studies in the USA, based on hospital
data provided voluntarily to the National Cancer Patient Data
Base, showed that adenocarcinomas (Howe et al, 1999) and
sarcomas (Howe et al, 2001) of the duodenum had significantly
lower survival than those in the jejunum and ileum. A population-
based study using Swedish Cancer Registry data also showed
that adenocarcinomas of the duodenum had the worst prognosis
(Zar et al, 1996).
Lower survival for duodenal tumours is clinically plausible.
Surgical management may involve duodenopancreatectomy, which
is associated with much higher mortality and morbidity than
resection of jejunal or ileal tumours (Al-Sharaf et al, 1999), and
vascular invasion often limits surgery. Not all patients with
duodenal tumours would be resectable, and surgery is the only
curative treatment. In this study, the proportion of patients with
duodenal tumours aged 70 years or over was higher than for
jejunal or ileal malignancies. Howe et al (1999) found that only
about half of duodenal tumours were treated by surgery of curative
intent, compared with 90% for jejunal and ileal tumours.
Improvement in survival from small intestinal tumours has been
reported from Sweden by Zar et al (1996) in their population-
based study. The relative hazard of death from adenocarcinoma of
the small intestine in the late 1980s was significantly lower than for
1960–1970. The improvement was confined to duodenal adeno-
carcinomas and did not affect tumours of the jejunum or ileum.
Here, we found similar improvements in survival for duodenal,
jejunal and ileal tumours, but the trend was statistically significant
only for duodenal tumours.
Several explanations are possible for the overall improvement in
survival for small intestinal tumours in England and Wales.
Survival for most cancers diagnosed during 1971–1990 has
improved steadily (Coleman et al, 1999). This can be attributed
to improvement in general cancer care, including improvement in
imaging techniques (Ullerich et al, 2001; Beal et al, 2002; de
Mascarenhas-Saraiva and da Silva Arau `jo Lopes, 2003). Increased
use of faecal occult blood tests and increased awareness of
symptoms may also have contributed to earlier diagnosis. Biologic
and environmental factors influencing expression and behaviour
of the tumours cannot be excluded (Adami et al, 1989).
Most of the improvement was seen in the first year after
diagnosis, with more modest gains in 5- and 10-year survival. No
major new treatment modalities have been introduced (Zar et al,
1996) and chemotherapy has not been systematically evaluated
(Copson and Iveson, 2003), so this pattern of improvement in
survival suggests that perioperative complications have become
less common, and the proportion of patients who are effectively
cured of their malignancy has not improved.
A major advantage of this study is the population-based data on
more than 5600 patients with small intestinal cancer diagnosed in
England and Wales over the 20-year period 1971–1990. All data
were collected using multiple sources of information in a uniform
manner, regardless of the time period and centre of diagnosis.
Nearly all persons newly diagnosed with a small intestinal tumour
in a population of over 50 million will have been registered,
avoiding the selection bias that is common in hospital case series.
This study has several limitations. Incidence and survival trends
for jejunal and ileal tumours could only be studied from 1979,
when they were first distinguished from other intestinal tumours
in the ICD. Stage of disease is an important prognostic factor but
it was not available in the national data. The use of ecological
measures of deprivation was imposed because no individual
measures are available, but this could only have attenuated the
significant association we observed between deprivation and
survival. Evidence is also available that small-area indicators of
deprivation do reflect individual disadvantage in relation to health
(Sloggett and Joshi, 1998).
In conclusion, survival from small intestinal malignancy in
England and Wales has improved, possibly owing to earlier
diagnosis and better treatment. Survival varies widely by
subsite within the small bowel and by morphologic type.
Further studies are needed to assess the impact of endoscopic
examination on early detection and improved survival. Linkage of
population-based cancer registry data with detailed clinical data on
diagnosis, pathology and treatment would improve the explana-
tory power of studies such as this: the results could better inform
healthcare planners about sustainable measures for improved
survival.
Table 3 Adjusted excess hazard ratios (EHR) and 95% confidence intervals (CI) for short-term and longer-term follow-up, by period of diagnosis and
subsite: England and Wales, adults diagnosed with small intestinal cancer 1979–1990 and followed up to 1995
Duration of follow-up
Duodenum
a Jejunum
b Ileum
c Unspecified site
d
Period of diagnosis EHR 95% CI EHR 95% CI EHR 95% CI EHR 95% CI
1 year
1979–1982 1.00 — 1.00 — 1.00 — 1.00 —
1983–1986 0.85 0.69–1.05 0.95 0.66–1.36 1.05 0.79–1.39 0.99 0.81–1.22
1987–1990 0.74 0.60–0.91 0.67 0.45–0.99 0.79 0.59–1.07 0.79 0.65–0.98
Trend
e 0.86 0.78–0.95 0.85 0.70–1.03 0.89 0.77–1.03 0.89 0.81–0.99
5 years
1979–1982 1.00 1.00 1.00 1.00
1983–1986 1.05 0.88–1.25 0.97 0.73–1.28 1.03 0.83–1.27 1.16 0.97–1.39
1987–1990 0.86 0.72–1.02 0.74 0.55–1.00 0.88 0.70–1.11 1.13 0.96–1.34
Trend 0.90 0.83–0.99 0.88 0.75–1.02 0.92 0.82–1.03 0.91 0.83–0.99
Excess hazard ratios estimated separately for each subsite. Final model for each subsite includes only those covariates that significantly improved the goodness of fit (see text).
Data from 1979–1990 only because jejunal tumours were not separately identifiable before 1979.
aCovariates age, deprivation, morphology.
bCovariates deprivation,
morphology.
cCovariates age, morphology.
dCovariates age, deprivation, region, morphology.
eRatio of the excess hazard of death between successive calendar periods of
diagnosis, after adjustment for covariates that significantly improved the goodness of fit.
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